ClinicalTrials.gg
CompletedNCT01304498Updated Dec 14, 2018Results posted

Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

A Phase 3 interventional study of V503 and GARDASIL in Human Papillomavirus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 9 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
9 Years to 15 Years
Sex
Female
01

Study summary

Primary objective:

  • To demonstrate that administration of V503 induces non-inferior Geometric Mean Titers (GMTs) (for serum anti-HPV16 and anti-HPV18) compared to GARDASIL.

Secondary objectives:

  • To evaluate the tolerability of V503 in 9-15 year-old girls.
  • To summarize humoral immune response (anti-HPV 6, 11, 16, 18) induced by V503 or GARDASIL.
02

Conditions studied

  • Human Papillomavirus
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 15 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female from 9 to 15 years old.
  • Good physical health.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to any vaccine component.
  • History of severe allergic reaction.
  • Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
  • Pregnant subject.
  • or immunodeficient subject.
  • Splenectomy.
  • Receipt of medication / vaccine that may interfere with study assessment.
  • Fever
  • History of a positive test for HPV, prior receipt of HPV vaccine or prior participation to HPV trial.
  • Any condition that might interfere with study assessment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    V503

    9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6

    Biological: V503

  • Active comparator
    GARDASIL

    Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6

    Biological: GARDASIL

Interventions

  • BiologicalV503

    9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine

    Also known as: 9vHPV vaccine

  • BiologicalGARDASIL

    Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine

    Also known as: qHPV vaccine

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) to HPV Types 16 and 18

    Serum antibodies to HPV types 16 and 18 were measured with a Competitive Luminex Immunoassay.

    Time frame: 4 weeks postdose 3 (Month 7)

Secondary outcomes

  1. GMTs to HPV Types 6 and 11

    Serum antibodies to HPV types 6 and 11 were measured with a Competitive Luminex Immunoassay.

    Time frame: 4 weeks postdose 3 (Month 7)

  2. Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18

    Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck Units/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24. The percentage of participants who were seropositive according to these cutoffs was assessed.

    Time frame: 4 weeks postdose 3 (Month 7)

  3. Percentage of Participants With One or More Adverse Events

    An adverse event is defined as any unfavourable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine, is also an adverse event. The percentage of participants with one or more adverse events was assessed.

    Time frame: Up to Month 7

  4. Percentage of Participants With One or More Injection-site Adverse Reactions

    The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.

    Time frame: Up to 5 days after any vaccination

  5. Percentage of Participants With One or More Systemic Adverse Events

    The percentage of participants with one or more systemic adverse events was assessed.

    Time frame: Up to 15 days after any vaccination

  6. Percentage of Participants With Maximum Oral Temperature ≥37.8°C

    The percentage of participants with maximum oral temperature ≥37.8°C was assessed.

    Time frame: Up to 15 days after any vaccination

  7. Percentage of Participants With One or More Serious Adverse Events

    A serious adverse event is an adverse event that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or may jeopardize the participant and may require medical or surgical intervention. The percentage of participants with one or more serious adverse events was assessed.

    Time frame: Up to Month 7

07

Results

Posted Aug 22, 2017

Participant flow

A total of 603 participants were screened and 600 were randomized

Participant flow — Overall Study
MilestoneV503GARDASIL
Started300300
Received ≥1 dose300300
Completed294295
Not completed65
Withdrew: Adverse event11
Withdrew: Withdrawal by subject23
Withdrew: Protocol violation10
Withdrew: Lost to follow-up21

Outcome measures

PrimaryGeometric Mean Titers (GMTs) to HPV Types 16 and 18

Serum antibodies to HPV types 16 and 18 were measured with a Competitive Luminex Immunoassay.

Time frame:
4 weeks postdose 3 (Month 7)
Reported as:
Geometric mean · milli Merck Units/mL
Geometric Mean Titers (GMTs) to HPV Types 16 and 18
milli Merck Units/mLV503GARDASIL
HPV Type 16 (n=276, 270)6739.5 (6134.5 to 7404.1)6887.4 (6220.8 to 7625.5)
HPV Type 18 (n=276, 269)1956.6 (1737.3 to 2203.7)1795.6 (1567.2 to 2057.3)
Statistical analysis
  • V503 vs GARDASIL · ANOVA · p = <0.001 · Gmt ratio: 0.97 · 95% CI 0.85 to 1.11GMT ratio = GMT (V503) / GMT (Gardasil)
  • V503 vs GARDASIL · ANOVA · p = <0.001 · Gmt ratio: 1.08 · 95% CI 0.91 to 1.29GMT ratio = GMT (V503) / GMT (Gardasil)
SecondaryGMTs to HPV Types 6 and 11

Serum antibodies to HPV types 6 and 11 were measured with a Competitive Luminex Immunoassay.

Time frame:
4 weeks postdose 3 (Month 7)
Reported as:
Geometric mean · milli Merck Units/mL
GMTs to HPV Types 6 and 11
milli Merck Units/mLV503GARDASIL
HPV Type 6 (n=273, 261)1679.4 (1518.9 to 1856.9)1565.9 (1412.2 to 1736.3)
HPV Type 11 (n=273, 261)1315.6 (1183.8 to 1462.0)1417.3 (1274.2 to 1576.5)
SecondaryPercentage of Participants Who Are Seropositive for HPV Types 6/11/16/18

Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck Units/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24. The percentage of participants who were seropositive according to these cutoffs was assessed.

Time frame:
4 weeks postdose 3 (Month 7)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18
Percentage of participantsV503GARDASIL
HPV Type 6 (n=273, 261)100 (98.7 to 100)100 (98.6 to 100)
HPV Type 11 (n=273, 261)100 (98.7 to 100)100 (98.6 to 100)
HPV Type 16 (n=276, 270)100 (98.7 to 100)100 (98.6 to 100)
HPV Type 18 (n=276, 269)100 (98.7 to 100)100 (98.6 to 100)
SecondaryPercentage of Participants With One or More Adverse Events

An adverse event is defined as any unfavourable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine, is also an adverse event. The percentage of participants with one or more adverse events was assessed.

Time frame:
Up to Month 7
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Adverse Events
Percentage of participantsV503GARDASIL
Percentage of Participants With One or More Adverse Events96.0 (87.9 to 94.5)93.7 (84.1 to 91.7)
SecondaryPercentage of Participants With One or More Injection-site Adverse Reactions

The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Injection-site Adverse Reactions
Percentage of participantsV503GARDASIL
Percentage of Participants With One or More Injection-site Adverse Reactions91.6 (87.9 to 94.5)88.3 (84.1 to 91.7)
SecondaryPercentage of Participants With One or More Systemic Adverse Events

The percentage of participants with one or more systemic adverse events was assessed.

Time frame:
Up to 15 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Systemic Adverse Events
Percentage of participantsV503GARDASIL
Percentage of Participants With One or More Systemic Adverse Events47.5 (41.7 to 53.3)52.0 (46.2 to 57.8)
SecondaryPercentage of Participants With Maximum Oral Temperature ≥37.8°C

The percentage of participants with maximum oral temperature ≥37.8°C was assessed.

Time frame:
Up to 15 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Maximum Oral Temperature ≥37.8°C
Percentage of participantsV503GARDASIL
Percentage of Participants With Maximum Oral Temperature ≥37.8°C6.7 (4.1 to 10.1)3.3 (1.6 to 6.0)
SecondaryPercentage of Participants With One or More Serious Adverse Events

A serious adverse event is an adverse event that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or may jeopardize the participant and may require medical or surgical intervention. The percentage of participants with one or more serious adverse events was assessed.

Time frame:
Up to Month 7
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Serious Adverse Events
Percentage of participantsV503GARDASIL
Percentage of Participants With One or More Serious Adverse Events0.30.7

Adverse events

Collected over All adverse events: up to 15 days after each vaccination; serious adverse events: up to Month 7. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V503—1/299 (0.3%)280/299 (93.6%)
GARDASIL—2/300 (0.7%)274/300 (91.3%)
Most frequent serious events
Most frequent serious events
EventV503GARDASIL
AnaemiaBlood and lymphatic system disorders1/2990/300
Pulmonary vasculitisRespiratory, thoracic and mediastinal disorders1/2990/300
Complex partial seizuresNervous system disorders0/2991/300
Henoch-Schonlein purpuraSkin and subcutaneous tissue disorders0/2991/300
Most frequent other events
Most frequent other events
EventV503GARDASIL
Injection-site painGeneral disorders269/299266/300
Injection-site swellingGeneral disorders144/299109/300
Injection-site erythemaGeneral disorders102/29988/300
HeadacheNervous system disorders57/29957/300
PyrexiaGeneral disorders22/29917/300
Oropharyngeal painRespiratory, thoracic and mediastinal disorders16/29917/300
NauseaGastrointestinal disorders16/29916/300
NasopharyngitisInfections and infestations5/29916/300

Baseline characteristics

Randomized participants

Age, Continuous
Age, Continuous(Years)V503GARDASILTotal
Mean12.6 ± 1.912.6 ± 1.912.6 ± 1.9
Age, Customized
Age, Customized(Participants)V503GARDASILTotal
9 to 12 years old150150300
13 to 15 years old150150300
Sex: Female, Male
Sex: Female, Male(Participants)V503GARDASILTotal
Female300300600
Male000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil(R) in 9-15-Year-Old Girls. Pediatr Infect Dis J. 2015 Sep;34(9):992-8. doi: 10.1097/INF.0000000000000773. PubMed 26090572 ↗
  • Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016 Aug;138(2):e20154387. doi: 10.1542/peds.2015-4387. Epub 2016 Jul 15. PubMed 27422279 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2011 to primary completion in Dec 2011, 9 months.

Results were first posted in Aug 2017, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2011
First posted
Feb 25, 2011
StartActual
Feb 23, 2011
Primary completionActual
Dec 20, 2011
CompletionActual
Dec 20, 2011
Results first posted
Aug 22, 2017
Last update
Dec 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01304498
Responsible party
Sponsor
First posted
Feb 25, 2011
Start date
Feb 23, 2011
Primary completion
Dec 20, 2011
Completion
Dec 20, 2011
Results posted
Aug 22, 2017
Last update
Dec 14, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion